Antiresorptiva-assoziierte Kiefernekrosen

Fazit

Die Antiresorptiva-assoziierte Kiefernekrose stellt sowohl für den Zahnarzt, den Oralchirurgen als auch für den Mund-, Kiefer- und Gesichtschirurgen eine Herausforderung in der Prophylaxe und Früherkennung dar. Durch konsequente prophylaktische Maßnahmen lässt sich die Prävalenz der ONJ senken. Wohingegen früher eine antiresorptive Therapie als Kontraindikation für eine Implantation angesehen wurde, zeigen neuere Studien und Erkenntnisse, dass die Risikoevaluation im Vordergrund steht. Bei Einhaltung bestimmter Sicherheitskautelen ist eine Implantation auch bei Hochrisikopatienten möglich.

• Literatur

• 1 Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1117
• 2 Grötz KA. Risikopatienten in der ZMK (inkl. Impl. bei Risikopatienten). In: Grötz KA. Hrsg. Handbuch ZMK 2015: ZMK-Update 2015. Wiesbaden: Med Publico; 2015
• 3 von Moos R. Bisphosphonate treatment recommendations for oncologists. Oncologist 2005; 10 (Suppl. 01) 19-24
• 4 Arantes HP, Silva AG, Lazaretti-Castro M. Bisphosphonates in the treatment of metabolic bone diseases. Arq Bras Endocrinol Metabol 2010; 54: 206-212
• 5 Tsao C, Darby I, Ebeling PR. et al. Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg 2013; 71: 1360-1366
• 6 Pushalkar S, Li X, Kurago Z. et al. Oral microbiota and host innate immune response in bisphosphonate-related osteonecrosis of the jaw. Int J Oral Sci 2014; 6: 219-226
• 7 Thumbigere-Math V, Michalowicz BS, Hodges JS. et al. Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw. J Periodontol 2014; 85: 226-233
• 8 Walter C, Laux C, Sagheb K. Radiologic bone loss in patients with bisphosphonate-associated osteonecrosis of the jaws: a case-control study. Clin Oral Investig 2014; 18: 385-390
• 9 Ruggiero SL, Mehrotra B, Rosenberg TJ. et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-534
• 10 Ruggiero SL, Dodson TB, Assael LA. et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws – 2009 update. J Oral Maxillofac Surg 2009; 67 (05) Suppl 2-12
• 11 Groetz KA, Piesold JU, Al-Nawas B. S3-Leitlinie: Bisphosphonat-assoziierte Kiefernekrose (BP-ONJ) und andere Medikamenten-assoziierte Kiefernekrosen. AWMF 007–091, 2012. Im Internet: http://www.awmf.org/leitlinien/detail/II/007-091.html Stand: 22.01.2017
• 12 Smith MR, Saad F, Coleman R. et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379 (9810) 39-46
• 13 Groetz KA. Onko II: Supportive TU-Betreuung. In: Groetz KA, Hassfeld S, Schmidt-Westhausen AM. Hrsg. Handbuch MKG 2016: MKG-Update 2016. Wiesbaden: Med Publico; 2016
• 14 Guarneri V, Miles D, Robert N. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 2010; 122: 181-188
• 15 Christodoulou C, Pervena A, Klouvas G. et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009; 76: 209-211
• 16 zm-online. Rote-Hand-Brief für Zaltrap. 07/2016. Im Internet: http://www.zm-online.de/hefte/Rote-Hand-Brief-fuer-Zaltrap_344687.html Stand: 01.06.2016
• 17 Pilanci KN, Alco G, Ordu C. et al. Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?. Medicine (Baltimore) 2015; 94: e671
• 18 Ponzetti A, Pinta F, Spadi R. et al. Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district. Tumori 2016;
• 19 Grötz KA, Al-Nawas B. Persisting alveolar sockets – a radiologic symptom of BP-ONJ?. J Oral Maxillofac Surg 2006; 64: 1571-1572
• 20 Grötz KA. Patientenbezogener Laufzettel „Überweisung/Konsil vor Bisphosphonat-Therapie“, ASORS Arbeitsgemeinschaft Supportive Maßnahmen in der Onkologie, Rehabilitation und Sozialmedizin der Deutschen Krebsgesellschaft, Stand 06/2012. Im Internet: http://www.onkosupport.de/asors/content/e4126/e1743/e1861/e1862 Stand: 15.07.2016
• 21 Sim Ie W, Sanders KM, Borromeo GL. et al. Declining Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Cancer. J Clin Endocrinol Metab 2015; 100: 3887-3893
• 22 Bramati A, Girelli S, Farina G. et al. Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases. J Bone Miner Metab 2015; 33: 119-124
• 23 Vandone AM, Donadio M, Mozzati M. et al. Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. Ann Oncol 2012; 23: 193-200
• 24 Montefusco V, Gay F, Spina F. et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma 2008; 49: 2156-2162
• 25 Krimmel M, Ripperger J, Hairass M. et al. Does dental and oral health influence the development and course of bisphosphonate-related osteonecrosis of the jaws (BRONJ)?. Oral Maxillofac Surg 2014; 18: 213-218
• 26 Walter C, Al-Nawas B, Frickhofen N. et al. Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients. Head Face Med 2010; 6: 11
• 27 Treister N, Sheehy N, Bae EH. et al. Dental panoramic radiographic evaluation in bisphosphonate-associated osteonecrosis of the jaws. Oral Dis 2009; 15: 88-92
• 28 Stockmann P, Hinkmann FM, Lell MM. et al. Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. Clin Oral Investig 2010; 14: 311-317
• 29 Hoff AO, Toth BB, Altundag K. et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23: 826-836
• 30 Van den Wyngaert T, Claeys T, Huizing MT. et al. Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol 2009; 20: 331-336
• 31 Lazarovici TS, Yahalom R, Taicher S. et al. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. J Oral Maxillofac Surg 2009; 67: 850-855
• 32 Stockmann P, Vairaktaris E, Wehrhan F. et al. Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer 2010; 18: 449-460
• 33 Wilde F, Heufelder M, Winter K. et al. The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 111: 153-163
• 34 Vescovi P, Manfredi M, Merigo E. et al. Surgical approach with Er : YAG laser on osteonecrosis of the jaws (ONJ) in patients under bisphosphonate therapy (BPT). Lasers Med Sci 2010; 25: 101-113
• 35 Pautke C, Bauer F, Bissinger O. et al. Tetracycline bone fluorescence: a valuable marker for osteonecrosis characterization and therapy. J Oral Maxillofac Surg 2010; 68: 125-129
• 36 Longo F, Guida A, Aversa C. et al. Platelet rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw: personal experience and review of the literature. Int J Dent 2014; 2014: 298945
• 37 Norholt SE, Hartlev J. Surgical treatment of osteonecrosis of the jaw with the use of platelet-rich fibrin: a prospective study of 15 patients. Int J Oral Maxillofac Surg 2016; 45: 1256-1260
• 38 Groetz KA, Al-Nawas B. Laufzettel Biophosphonate Risiko-Evaluation bei antiresorptiver Therapie vor Implantation, 2013. Im Internet: http://www.dginet.de/web/dgi/laufzettel-bisphosphonate Stand: 15.07.2016
• 39 Kumar MN, Honne T. Survival of dental implants in bisphosphonate users versus non-users: a systematic review. Eur J Prosthodont Restor Dent 2012; 20: 159-162
• 40 Kasai T, Pogrel MA, Hossaini M. The prognosis for dental implants placed in patients taking oral bisphosphonates. J Calif Dent Assoc 2009; 37: 39-42
• 41 Siebert T, Jurkovic R, Statelova D, Strecha J. Immediate Implant Placement in a Patient With Osteoporosis Undergoing Bisphosphonate Therapy: 1-Year Preliminary Prospective Study. J Oral Implantol 2015; 41 Spec No: 360-365
• 42 Lazarovici TS, Yahalom R, Taicher S. et al. Bisphosphonate-related osteonecrosis of the jaw associated with dental implants. J Oral Maxillofac Surg 2010; 68: 790-796
• 43 Shabestari GO, Shayesteh YS, Khojasteh A. et al. Implant Placement in Patients with Oral Bisphosphonate Therapy: A Case Series. Clin Implant Dent Relat Res 2010; 12: 175-180
• 44 Kwon TG, Lee CO, Park JW. et al. Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment. Clin Oral Implants Res 2014; 25: 632-640
• 45 Buttchereit I, Scholz M, Frerich B. et al. . Periimplantoplastik bei Bisphosphonaten. Zahnärztliche Mitteilungen 2015; 8: 44-48
• 46 Walter C, Al-Nawas B, Wolff T. et al. Dental implants in patients treated with antiresorptive medication – a systematic literature review. Int J Implant Dent 2016; 2: 9